Evidence map›Paper›PMID 40796619›Full record

SynthesisScientific reports2025

Impact of sacubitril/valsartan on chronic heart failure patients with sleep-disordered breathing: a systematic review and meta-analysis.

Xuyuan Kuang, Chunyan Ye, Yongqiu Xie, E Wang, Na Chen, Chuyan Yang, Siting Zhong, Lu Liao

Abstract readSystematic ReviewMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xuyuan KuangDepartment of Hyperbaric Oxygen, Xiangya Hospital, Central South University, Xiangya Road87, Changsha, Hunan, 410008, Hunan, China.
Chunyan YeDepartment of Anesthesiology, Xiangya Hospital, Central South University, Changsha, China.
Yongqiu XieDepartment of Anesthesiology, Xiangya Hospital, Central South University, Changsha, China. yongqiu.xie@csu.edu.cn.
E WangDepartment of Anesthesiology, Xiangya Hospital, Central South University, Changsha, China.
Na ChenDepartment of Anesthesiology, Xiangya Hospital, Central South University, Changsha, China.
Chuyan YangDepartment of Rehabilitation Medicine, Jiangxi People's Hospital, Fenghe North Avenue 266, Nanchang, Jiangxi, China.
Siting ZhongDepartment of Rehabilitation Medicine, Jiangxi People's Hospital, Fenghe North Avenue 266, Nanchang, Jiangxi, China.
Lu LiaoDepartment of Rehabilitation Medicine, Jiangxi People's Hospital, Fenghe North Avenue 266, Nanchang, Jiangxi, China.

Funding

Natural Science Foundation of Hunan Province 2022JJ30972, 2024JJ5584Scientific Research Project of Hunan Provincial Health Commission No.B202319019225Traditional Chinese Medicine Project in Jiangxi Province No.2023B0185, No.2022A281
6 · The paper itself

Abstract

Chronic heart failure (CHF) affects 1-2% of adults in developed countries, with up to 50% experiencing sleep-disordered breathing (SDB). Sacubitril/valsartan (sac/val) has shown potential benefits on respiratory function, but its effect on SDB remains uncertain. This study aims to evaluates the effectiveness of sac/val on SDB and respiratory function in CHF patients. Electronic searches were conducted based on MEDLINE, EMBASE, Cochrane Library, and Web of Science using MeSH terms and relevant keywords. Apnea-hypopnea index (AHI) and central apnea index (CAI) were used as primary outcome. Statistical analysis was performed using Stata 15.1 SE, with Cochrane Q and I² statistics used for heterogeneity assessment. Publication bias and sensitivity analyses were conducted using various methods. Risk of bias was assessed using the MINORS and ROB 2.0 tools. Seven studies met inclusion criteria. Results indicated that sac/val significantly reduced AHI (mean difference [MD], -3.56; P < 0.001) and increased mean oxygen saturation (MD = 0.61; P < 0.001), although there was a modest rise in CAI (MD = 0.30; P = 0.049). The pooled analysis indicated a 22% reduction in CSA patients. The analysis demonstrated a statistically significant reduction in AHI and an improvement in SpO2 during sleep after using sac/val. While these findings suggest improvements in SDB, further high-quality research is needed to confirm these results and explore underlying mechanisms.

Indexed as

AminobutyratesAngiotensin Receptor AntagonistsBiphenyl CompoundsHeart FailureSleep Apnea SyndromesValsartanChronic DiseaseDrug CombinationsHumansTreatment OutcomeAminobutyratesAngiotensin Receptor AntagonistsBiphenyl CompoundsDrug Combinationssacubitril and valsartan sodium hydrate drug combinationValsartanHeart failureMeta-analysisSacubitril/valsartanSleep-disordered breathing

Identifiers

PMID40796619
PMCPMC12344083

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.